Literature DB >> 8794820

Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism.

H Karam1, D Heudes, P Bruneval, M F Gonzales, B M Löffler, M Clozel, J P Clozel.   

Abstract

High blood pressure results in cardiac hypertrophy and fibrosis, increased thickness and stiffness of large artery walls, and decreased renal function. The objective of our study was to assess the role of endothelin, angiotensin II, and high blood pressure in the end-organ damage observed in spontaneously hypertensive rats (SHR). For this purpose, SHR were treated for 10 weeks with either a mixed endothelin-A and endothelin-B receptor antagonist, bosentan (100 mg/kg per day), an angiotensin-converting enzyme inhibitor, enalapril (10 mg/kg per day), or a long-acting calcium antagonist, mibefradil (20 mg/kg per day). A group of SHR was left untreated, and a group of normotensive Wistar rats was used as control. At the end of treatment, maximal coronary blood flow was measured in isolated perfused hearts. Cardiac hypertrophy and fibrosis, aortic medial thickness, and extracellular matrix content were evaluated by quantitative morphometry. Proteinuria and urea and creatinine clearances were measured, and renal histopathology was assessed. SHR exhibited cardiac hypertrophy, perivascular fibrosis, and decreased maximal coronary blood flow. Aortic medial thickness was increased, whereas elastin density was decreased. Finally, SHR showed decreased urinary excretion and decreased urea and creatinine clearances. No renal histological lesions were observed. Although bosentan did not affect blood pressure, it normalized renal function and slightly decreased left ventricular hypertrophy and fibrosis. Enalapril and mibefradil were both effective in significantly decreasing blood pressure, left ventricular hypertrophy, and aortic medial thickness and improving coronary blood flow, but in contrast to bosentan, they did not improve creatinine clearance. We conclude that in SHR, high blood pressure plays a major role in end-organ damage and that endothelin may partly mediate renal dysfunction and cardiac remodeling independently of a direct hemodynamic effect.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794820     DOI: 10.1161/01.hyp.28.3.379

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  11 in total

Review 1.  The future of endothelin-receptor antagonism as treatment for systemic hypertension.

Authors:  Gabriel Vorobiof; Burns C Blaxall; John D Bisognano
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

2.  Bosentan, an endothelin receptor antagonist, reduces leucocyte adhesion and inflammation in a murine model of inflammatory bowel disease.

Authors:  Christoph Anthoni; Rudolf B Mennigen; Emile J M Rijcken; Mike G Laukötter; Hans-Ullrich Spiegel; Norbert Senninger; Guido Schürmann; Christian F Krieglstein
Journal:  Int J Colorectal Dis       Date:  2005-08-09       Impact factor: 2.571

Review 3.  Endothelin receptor antagonists and cardiovascular diseases of aging.

Authors:  M P Love; J J McMurray
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  The case for combining angiotensin-converting enzyme inhibitors and calcium-channel blockers.

Authors:  A A Taylor; S Sunthornyothin
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

Review 5.  Endothelin and its antagonists in hypertension: can we foresee the future?

Authors:  P Moreau; T J Rabelink
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

6.  Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease.

Authors:  Hong-Qiang Feng; Nate D Weymouth; Don C Rockey
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-03-19       Impact factor: 4.052

Review 7.  Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.

Authors:  R N Brogden; A Markham
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

8.  Cell and molecular regulation of endothelin-1 production during hepatic wound healing.

Authors:  Rong Shao; Zengdun Shi; Philip J Gotwals; Victor E Koteliansky; Jacob George; Don C Rockey
Journal:  Mol Biol Cell       Date:  2003-04-17       Impact factor: 4.138

Review 9.  Endothelin-receptor antagonists in arterial hypertension: further indications?

Authors:  Isabella Sudano; Matthias Hermann; Frank T Ruschitzka
Journal:  Curr Hypertens Rep       Date:  2007-03       Impact factor: 4.592

10.  The effect of multivitamin-multimineral supplementation on the health status of inbred Wistar and spontaneously hypertensive rat strains.

Authors:  Rosemarie U Höfler; Mahendra L Channa; Anand Nadar
Journal:  J S Afr Vet Assoc       Date:  2016-06-09       Impact factor: 1.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.